Dr Townsend on Understanding Prostate Cancer and the Utility of Genomic Sequencing


Jeffrey P. Townsend, PhD, discusses advancements in the understanding of prostate cancer care through the utility of genomic sequencing.

Jeffrey P. Townsend, PhD, Elihu Professor of Biostatistics, professor, Ecology and Evolutionary Biology, co-leader, Genomics, Genetics, & Epigenetics Research Program, Yale School of Public Health, discusses advancements in the understanding of prostate cancer care through the utility of genomic sequencing.

To begin, Townsend emphasizes that the number of prostate tumor samples that are available from patients who have been screened for whole exome or whole panel sequencing are consistently being utilized and therefore diminished. While there is a substantial repository of sequenced tumors, further analysis is needed to elucidate specific gene mutations and their implications across disease stages, he explains.

With the increasing availability of these samples, researchers are able to conduct stage-specific analyses, revealing nuanced insights into the mutational landscape of prostate cancer, Townsend expands. Furthermore, it is important to underscore the need for continued sample collection and analysis, as it allows for a more comprehensive understanding of disease trajectories, he states

In his research, Townsend shares that he observed that the distinct selective pressures on genes across different risk categories and disease stages vary. While there is a slight increase in the overall mutation rate as the disease progresses, the key finding lies in the differential selection of mutated genes, he reports. Notably, Townsend highlights that the genes targeted for mutations vary significantly depending on disease stage, particularly in metastatic cases.

These findings have implications for precision medicine in prostate cancer treatment, as researchers have the ability to tailor therapies to target specific genetic mutations through gaining a better understanding of the genetic alterations driving disease progression, he elucidates. This personalized approach holds promise for improving treatment efficacy and patient outcomes.

This research underscores the importance of genomic sequencing in elucidating the complex molecular landscape of prostate cancer. By analyzing large cohorts of sequenced tumors, researchers can identify key genetic mutations associated with disease progression and tailor treatments accordingly. This process of sample collection and analysis is crucial for advancing precision medicine in prostate cancer, Townsend concludes.

Related Videos
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Ashwin Kishtagari, MD
Somedeb Ball, MBBS